49th week of 2012 patent applcation highlights part 43 |
Patent application number | Title | Published |
20120308557 | Immunoglobulin Preparation - The present invention relates to the use of proline for reducing the viscosity of a protein preparation. | 2012-12-06 |
20120308558 | Methods of Using Antibodies That Bind The Glutamate Ligand Binding Region of Notch1 - Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth. | 2012-12-06 |
20120308559 | METHOD OF TREATING HEMOLYTIC DISEASE - Paroxysmal nocturnal hemoglobinuria or other hemolytic diseases are treated using a compound which binds to or otherwise blocks the generation and/or the activity of one or more complement components, such as, for example, a complement-inhibiting antibody. | 2012-12-06 |
20120308560 | Antineoplastic Combinations with mTOR Inhibitor, Trastuzumab and/or HKI-272 - A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described. | 2012-12-06 |
20120308561 | POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN THE PROCESS OF BONE REMODELING - This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling; variants and derivatives of the polynucleotides and corresponding polypeptides; uses of the polynucleotides, polypeptides, variants and derivatives; and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are, the isolation and identification of polynucleotides, polypeptides, variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes. | 2012-12-06 |
20120308562 | METHODS OF TREATING MESOTHELIOMA WITH A PI3K INHIBITOR COMPOUND - Methods are provided for treating mesothelioma patients with a dual PI3K/mTOR inhibitor, GDC-0980: (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin- | 2012-12-06 |
20120308563 | REGULATORY B CELLS (TBREGS) AND THEIR USE - Regulatory B cells (tBreg) are disclosed herein. These regulatory B cells express CD25 (CD25 | 2012-12-06 |
20120308564 | TREATMENT OF A METABOLIC DISORDER - The present disclosure relates to the field of metabolic disorders, including type II diabetes and obesity. Specifically, the disclosure relates to methods of treating and/or preventing a metabolic disorder with an IL-18 antagonist, in particular an anti-IL-18 antigen binding protein, in particular an anti-IL-18 antibody. | 2012-12-06 |
20120308565 | CHEMOKINE-IMMUNOGLOBULIN FUSION POLYPEPTIDES, COMPOSITIONS, METHOD OF MAKING AND USE THEREOF - This application is directed to chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates. The fusion polypeptides and conjugates can be used for treating chemokine receptor-mediated disorders and modulating inflammation, inflammatory cell motility, cancer cell motility, or cancer cell survival. | 2012-12-06 |
20120308566 | USE OF IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS - The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for treating diseases, such as various forms of cancer. | 2012-12-06 |
20120308567 | USE OF TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROLACTINOMA - The invention relates to methods and kits for the treatment of prevention of and lowering the chances of developing prolactinomas by the administration of a tyrosine kinase inhibitor, such as lapatinib. | 2012-12-06 |
20120308568 | PHARMACEUTICAL COMPOSITION FOR INHIBITING ABNORMAL PROLIFERATION OF CELLS - The present invention relates to a pharmaceutical composition for preventing or treating diseases related to abnormal proliferation of cells, comprising a cytoplasmic heat shock protein (Hsp)60 kDa inhibitor as an active ingredient, and to a screening method and a kit using the composition. According to the present invention, substances which inhibit expression of cytoplasmic Hsp 60 genes or inhibit activity of cytoplasmic Hsp 60 or inhibit binding between cytoplasmic Hsp 60 and IKK protein prevent interaction between cytoplasmic Hsp 60 and IKK complexes to make NF-κB path inactive, and thus induce apoptosis. Therefore, the substances can be valuably used in preventing or treating diseases related to abnormal proliferation of cells, such as cancer, inflammatory diseases or hyperproliferative vascular diseases. | 2012-12-06 |
20120308569 | GENE PRODUCTS DIFFERENTIALLY EXPRESSED IN CANCEROUS CELLS - The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of cancer cells. These methods are useful for treating cancer. | 2012-12-06 |
20120308570 | METHODS FOR TREATING DISEASES - The present invention relates to methods of modulating the level of inducible nitric oxide synthase (iNOS) in a cell which comprises administering to the cell a compound which modulates binding of SPRY domain-containing SOCS box protein (SSB) to iNOS, and/or a compound which modulates SSB activity in the cell. Further provided are methods of treating or preventing disease in a subject by modulating the level of iNOS in a cell, as well as compounds which modulate binding of SSB to iNOS and compounds which modulate SSB activity. | 2012-12-06 |
20120308571 | ANTI-PODOPLANIN ANTIBODY, AND PHARMACEUTICAL COMPOSITION CONTAINING ANTI-PODOPLANIN ANTIBODY - Disclosed are: an anti-podoplanin antibody which has a high binding activity and a high effector activity and has low antigenicity in humans or mice; and others. Specifically disclosed are: a chimeric antibody comprising an anti-podoplanin antibody for which an epitope is a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:1 (excluding rat NZ-1 antibody having a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:2 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:3), and a heavy chain complementarity determining region and a light chain complementary determining region of the anti-podoplanin antibody; and others. | 2012-12-06 |
20120308572 | Protofibril-Binding Antibodies and Their Use in Therapeutic and Diagnostic Methods for Parkinson's Disease, Dementia with Lewy Bodies and Other Alpha-Synucleinopathies - Antibodies and fragments thereof have high affinity for human α-synuclein protofibrils and low binding of α-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting α-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with α-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with α-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with α-synuclein pathology, and in methods for reducing or inhibiting α-synuclein aggregation by administration of such an antibody or fragment. | 2012-12-06 |
20120308573 | Anti-IL-23 Antibodies, Compositions, Methods and Uses - An anti-IL-23 antibody, including isolated nucleic acids that encode at least one anti-IL-23 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. | 2012-12-06 |
20120308574 | HUMAN MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO VCAM-1 AND A COMPOSITION FOR TREATING AN INFLAMMATORY DISEASE OR A CANCER COMPRISING THE SAME - The present invention relates to a human monoclonal antibody that specifically binds to VCAM-1, and a therapeutic composition for the treatment of inflammatory disease or cancer comprising the same. The human monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human or mouse endothelial cell, effectively inhibits leukocyte adhesion to activated endothelial cells expressing VCAM-1, and shows a low immunogenicity, thereby being used for the treatment of cancer or inflammatory disease such as asthma, rhinitis, arthritis, multiple sclerosis, bowel disease, arteriosclerosis, myocardial infarction and transplant rejection. | 2012-12-06 |
20120308575 | FULL HUMAN ANTI-TNF-ALPHA MONOCLONAL ANTIBODY, PREPARATION METHOD AND USE THEREOF - The present invention provides a full human anti-TNF-α monoclonal antibody, the preparation method and use thereof. The antibody in the present invention has an amino acid sequence of heavy chain variable region as shown in SEQ ID NO: 6 and an amino acid sequence of light chain variable region as shown in SEQ ID NO: 8. The antibody in the present invention can be used to prepare medicines for the treatment of autoimmune disorders. | 2012-12-06 |
20120308576 | MONOCLONAL AND OLIGOCLONAL ANTI-EGFR ANTIBODIES FOR USE IN THE TREATMENT OF TUMORS EXPRESSING PREDOMINANTLY HIGH AFFINITY EGFR LIGANDS OR TUMORS EXPRESSING PREDOMINANTLY LOW AFFINITY EGFR LIGANDS - Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-EGFR monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations. | 2012-12-06 |
20120308577 | DNA VACCINES AND METHODS FOR THE PREVENTION OF TRANSPLANTATION REJECTION - Methods for preventing, delaying the onset of, or treating rejection of an allograft using a DNA vaccine, where the vaccine can comprise a polynucleotide encoding a pro-apoptotic protein, like BAX and/or a polynucleotide encoding an autoantigen or donor antigen, like secreted glutamic acid decarboxylase 55. Administering one of the DNA vaccines to a transplant recipeint, as described herein, can induce a donor specific tolerogenic response. | 2012-12-06 |
20120308578 | SLE-DC-MEDIATED ENHANCED IgG- AND IgA-SECRETING B CELL RESPONSES - The present invention provides a method for treating a patient at risk for or diagnosed systemic lupus erythematosus (SLE) by determining the overall expression of syndecan-1 in one or more cells of a patient suspected of having SLE; and predicting the efficacy of a therapy with a pharmaceutical agent for treating the patient, wherein a decrease in the overall expression of syndecan-1 in the patient cells when compared to the expression of syndecan-1 in normal cells indicates a predisposition to responsiveness to anti-neoplastic agent therapy, wherein the therapy comprises administering an effective amount of the pharmaceutical agent to the patient. | 2012-12-06 |
20120308579 | METHOD OF MAKING AND USING A COMPOSITION FOR DELIVERING VIRAL IMMUNOGEN IMMUNOGLOBULIN INHIBITOR TO THE NASAL PHARYNGEAL MEMBRANE - A method of making and using an immunoglobulin package containing one or more viral inhibitors specifically targeted to receptor factors in viruses is provided. The immunoglobulin package substantially prevents the binding of viral immunogens in respiratory tracts of humans or animals and mechanically prevents a virus from reproducing in the nasal cavity. The immunoglobulins are made by inoculating cows with the immunogen(s), allowing the immune response to develop in the animal, harvesting the plasma containing the immunoglobulins, manufacturing the plasma to create a gel or liquid to swab, spray or mist into the nostril of the host. This method will prevent the spread of disease and give the host time to produce their own immunity to the virus for future protection. The invention may be utilized to substantially reduce or eliminate viruses that decrease the health of humans or animals such as Influenza and other respiratory viruses. | 2012-12-06 |
20120308580 | HEPATITUS B VIRUS SPECIFIC ANTIBODY AND USESE THEREOF - There is provided at least one isolated TCR-like antibody or fragment thereof, wherein the antibody or fragment thereof is capable of specifically binding to at least one HBV derived peptide. | 2012-12-06 |
20120308581 | COMPOSITIONS AND METHODS FOR DETECTING TLR3 - The present invention relates to antibodies, antibody fragments, and derivatives thereof that specifically bind to TLR3 cell receptors present on the surface of cells. The invention also relates to hybridomas producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to detect TLR3 levels on the surface of cells, and the use of such antibodies and compositions for diagnostic or therapeutic purposes in subjects. | 2012-12-06 |
20120308582 | MOLECULES AND METHODS FOR MODULATING TMEM16A ACTIVITIES - The present invention provides molecules that bind to TMEM16A (“TMEM16A binding molecules”), particularly human or humanized antibodies and antibody drug conjugates that bind to human TMEM16A and modulate its functions. Epitopes of TMEM16A and molecules that bind these epitopes are also provided herein. | 2012-12-06 |
20120308583 | USE OF GCC LIGANDS - Proliferation of colorectal, gastric and esophageal cancer cells is inhibited by administering ST receptor ligand. The number of ST receptor molecules on the surface of a colorectal cell or metastasized colorectal cancer cell are increased by administering an ST receptor ligand such that ligand comes into contact with an ST receptor on the surface of the colorectal cell. Pharmaceutical compositions comprise sterile, pyrogen free ST receptor ligand and a pharmaceutically acceptable carrier or diluent. Metastasized colorectal cancer is treated or imaged by increasing the number of ST receptor molecules on the surface of a metastasized colorectal cancer cell and then administering a pharmaceutical composition containing components that target the ST receptor for delivery of a therapeutic agent or imaging agent. Methods of detecting metastasized colorectal cancer are disclosed. Methods of delivering active compounds to a colorectal cell in an individual are disclosed. | 2012-12-06 |
20120308584 | PROTEIN-ACTIVE AGENT CONJUGATES AND METHOD FOR PREPARING THE SAME - The invention provides protein-active agent conjugates having an amino acid motif that can be recognized by an isoprenoid transferase. The invention also provides compositions containing the conjugates, as well as methods for making the conjugates and compositions. The invention further provides methods for using the conjugates to deliver the active agent to a target cell, as well as methods for using the conjugates to treat a subject in need thereof (e.g., a subject in need of the active agent). | 2012-12-06 |
20120308585 | METHODS AND COMPOSITIONS FOR USE IN CELLULAR THERAPIES - The present invention provides methods for the intralymphatic administration of cellular therapies. Further aspects of the invention provide compositions, kits and uses thereof related to such methods. | 2012-12-06 |
20120308586 | COMPOSITION BASED ON EXTRA VIRGIN OLIVE OILS - This invention relates to a composition based on a mixture of different olive oils, preferably virgin and extra virgin olive oils, from ecological farms, and to the use thereof in the treatment or prevention of different disorders in humans and animals. Moreover, this invention also relates to a dermatological/dermocosmetic preparation that comprises the composition of this invention and to the use of this dermatological/dermocosmetic preparation in the treatment of skin disorders in humans and animals. Underlying these systemic and/or skin disorders, there are metabolic and immunoinflammatory-oxidative alterations, which may be positively modified by the systemic (oral) or topical (cutaneous) use of the composition of this invention. The special physical-chemical structure of the composition allows for a better digestive and cutaneous arrangement. | 2012-12-06 |
20120308587 | NEPRILYSIN INHIBITORS - In one aspect, the invention relates to compounds having the formula: | 2012-12-06 |
20120308588 | NEPRILYSIN INHIBITORS - In one aspect, the invention relates to compounds having the formula: | 2012-12-06 |
20120308589 | SINOMENINE DERIVATIVES, SYNTHETIC METHODS AND USES THEREOF - The invention relates to sinomenine derivatives, methods for their synthesis and their applications. The sinomenine derivatives include oxidation derivatives, and C-10 substituted sinomenine derivatives. Based on the readily oxidizable phenol group on sinomenine structure, using oxidation, oxidative dearomatization, or conjugated addition aromatization, one can introduce C-10 substitutions to synthesize the sinomenine derivatives. The sinomenine derivatives of the invention have the following structures: | 2012-12-06 |
20120308590 | IMP-3 OLIGOPEPTIDES AND VACCINES INCLUDING THE SAME - Oligopeptides having cytotoxic T cell inducibility and suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. Notable examples include oligopeptides having the amino acid sequence of SEQ ID NO: 1, 3, 5 or 6, wherein 1, 2, or several amino acids are optionally substituted, deleted, inserted or added so long as they retain the cytotoxic T cell inducibility of the original oligopeptides. Pharmaceutical formulations or “drugs” related to such oligopeptides suitable for treating or preventing cancers or tumors, as well as the post-operative recurrence thereof, are also described. | 2012-12-06 |
20120308591 | TMEM22 PEPTIDES AND VACCINES INCLUDING THE SAME - Isolated peptides composed of the amino acid sequence of SEQ ID NO: 33 or fragments thereof that bind to HLA antigens and have cytotoxic T lymphocyte (CTL) inducibility and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical agents, substances and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors. | 2012-12-06 |
20120308592 | Immunogenic HPV L2-Containing VLPs and Related Compositions, Constructs, and Therapeutic Methods - The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of human papillomavirus (HPV) infections and related disorders, including cervical cancer and persistent infections associated with HPV. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against HPV L2 and protect against HPV challenge in vivo. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against HPV infection, confer immunity against HPV infection, protect against HPV infection, and reduce the likelihood of infection by HPV infection. | 2012-12-06 |
20120308593 | Immunological Compositions for HIV - The disclosure relates to immunological compositions for vaccinating human beings against infection by the Human Immunodeficiency Virus (HIV). | 2012-12-06 |
20120308594 | HCV CLADE AND PROTOTYPE SEQUENCES THEREOF - The current invention relates to a previously unrecognized clade of HCV genotypes as well as to diagnostic, prophylactic and therapeutic applications of nucleic acids, proteins, and antibodies to said protein, derived of or based on the newly characterized hepatitis C viruses. | 2012-12-06 |
20120308595 | Novel Immunogenic Compositions For The Prevention And Treatment of Meningococcal Disease - The present invention relates to | 2012-12-06 |
20120308596 | NOVEL STREPTOCOCCUS ANTIGENS - proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of | 2012-12-06 |
20120308597 | SEROLOGIC CORRELATES OF PROTECTION AGAINST BACILLIS ANTHRACIS INFECTION - Regions of | 2012-12-06 |
20120308598 | MALARIA VACCINES BASED ON APICOMPLEXAN FERLINS, FERLIN-LIKE PROTEINS AND OTHER C2-DOMAIN CONTAINING PROTEINS - The present invention relates to peptides comprising at least one antigenic determinant or epitope of an apicomplexan Ferlin, Ferlin-like protein and/or another C2-domain containing protein for use as malaria vaccines. It further relates to compositions comprising said peptides and to the use of such compositions as malaria vaccines. | 2012-12-06 |
20120308599 | VACCINE AND METHODS OF USE AGAINST STRONGYLOIDES STERCORALIS INFECTION - The polynucleotide encoding the SSIR gene from the nematode | 2012-12-06 |
20120308600 | POLYSACCHARIDE IMMUNOGENS CONJUGATED TO E. COLI CARRIER PROTEINS - proteins have been identified that are useful as carrier proteins to improve a response to a polysaccharide immunogen conjugated to such protein. In particular, AcfD precursor protein (orf3526 polypeptide), Flu antigen 43 protein (orf1364 polypeptide), and Sel1 repeat-containing protein (upec-5211 polypeptide) have been shown to be effective. Additionally, these | 2012-12-06 |
20120308601 | METHODS AND MATERIALS FOR TREATING CANCER - This document provides methods and materials related to treating cancer. For example, methods and materials for using nucleic acid libraries to treat cancer are provided. | 2012-12-06 |
20120308602 | Recombinant RSV Virus Expression Systems And Vaccines - The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene. | 2012-12-06 |
20120308603 | DNA VACCINE AGAINST VIRUS OF YELLOW FEVER - The present invention relates to vaccines of DNA that code for specific viral sequences. The DNA vaccines against yellow fever according to the invention are based on the sequence that codes for the yellow fever virus envelope protein (p/YFE). Besides the wild p/YFE construct, sequence E was also fused with the sequence that codes for the human lysosome-associated membrane protein (h-LAMP), generating the construct (pL/YFE). The results of the invention are considered to be very promising, since both constructs can induce T-cell response against the same epitopes induced by the 17DD vaccine, and the pL/YFE construct can also induce a satisfactory concentration of neutralising antibodies. The pL/YFE vector was inoculated in mice, before intracerebral challenge with the virus of yellow fever. Surprisingly, 100% of the mice immunised with pL/YFE survived the challenge. | 2012-12-06 |
20120308604 | ADJUVANT FOR THE PREPARATION OF VACCINE COMPOSITIONS INTENDED FOR THE PREVENTION OF COCCIDIOSIS - A vaccine adjuvant which, based on the 100% mass thereof, includes between 10% and 95% of a mineral oil containing: between 0.05 mass-% and 10 mass-% hydrocarbon chains having less than 16 carbon atoms, and between 0.05 mass-% and 5 mass-% hydrocarbon chains having more than 28 carbon atoms. In addition, the adjuvant has a P/N ratio, corresponding to the ratio of the mass quantity of the paraffinic hydrocarbon chains to the mass quantity of the naphthenic hydrocarbon chains, of between 2.5 and 3, the adjuvant being intended for the production of a vaccine composition to prevent coccidiosis. | 2012-12-06 |
20120308605 | Pharmaceutical Composition of Killed Cells with Substantially Retained Immunogenicity - This invention discloses the process for lyophilisation of the treated cells which comprises the use of a solution containing Trehalose along with amphipathic polymer Polyvinylpyrrolidone. Further the invention discloses the process treating cancer cells, freezing, lyophilizing and reconstituting. Immunomodulator treated dead, but intact cancerous cells were recovered, which can subsequently be used for cancer immunotherapy. | 2012-12-06 |
20120308606 | BICYCLIC DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS - Bicyclic derivatives useful as ion channel antagonists are disclosed herein. The compositions thereof are useful for treating or relieving pain-related conditions. | 2012-12-06 |
20120308607 | PRODUCTION AND USE OF HUMAN CD124- AND CD-116-POSITIVE TUMOR CELL LINES IN THE PRODUCTION OF ALLOGENIC OR SEMI-ALLOGENIC IMMUNOTHERAPY AGENTS - The invention is related to the production and use of CD124+ and CD116+ cell lines for the production of effective dendritic cells (DC) using stimulatory molecules, their use in the production of allogenic or semi-allogenic immunotherapeutic agents and the use thereof in the treatment or prophylaxis of immune diseases. Furthermore, the invention is related to the use of CD124+ and CD116+ tumor cell lines, preferably also being CD34+, as model and yeast systems for testing the DC biology and for testing substances having an impact on the immune system and on the conditioning thereof. | 2012-12-06 |
20120308608 | INTERFERON-INDUCING COMPOUNDS AND USES THEREOF - Provided herein are Compounds that induce interferon production and methods for identifying such Compounds. Also provided herein are compositions comprising such Compounds and methods of using such Compounds to treat interferon-sensitive diseases such as viral infections, cancer, and multiple sclerosis. | 2012-12-06 |
20120308609 | 6-AMINO-2--9-[5-(1-PIPERIDINYL)-7,9-DIHYDRO-8H-PURIN-8-ONE MALEATE - The present invention relates to a compound which is 6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one: | 2012-12-06 |
20120308610 | Materials and Methods for Altering an Immune Response to Exogenous and Endogenous Immunogens, Including Syngeneic and Non-Syngeneic Cells, Tissues or Organs - Disclosed herein are materials and methods for modulating an immunologically adverse response to an exogenous or endogenous immunogen, including a cell, tissue, or organ associated immunogen. An implantable material comprising cells, such as but not limited to endothelial cells, anchored or embedded in a biocompatible matrix can modulate an adverse immune or inflammatory reaction to exogenous or endogenous immunogens, including response to non-syngeneic or syngeneic cells, tissues or organs, exogenous immunogens or stimuli, as well as ameliorate an autoimmune condition. The implantable material can be provided prior to, coincident with, or subsequent to occurrence of the immune response or inflammatory reaction. The implantable material can induce immunological acceptance in a transplant patient, reduce graft rejection and reduce donor antigen immunogenicity. | 2012-12-06 |
20120308611 | FIBROUS PROTEIN FUSIONS AND USE THEREOF IN THE FORMATION OF ADVANCED ORGANIC/INORGANIC COMPOSITE MATERIALS - The claimed invention provides a fusion polypeptide comprising a fibrous protein domain and a mineralization domain. The fusion is used to form an organic-inorganic composite. These organic-inorganic composites can be constructed from the nano- to the macro-scale depending on the size of the fibrous protein fusion domain used. In one embodiment, the composites can also be loaded with other compounds (e.g., dyes, drugs, enzymes) depending on the goal for the materials, to further enhance function. This can be achieved during assembly of the material or during the mineralization step in materials formation. | 2012-12-06 |
20120308612 | COMPOSITIONS AND METHODS FOR PREPARATION OF POORLY WATER SOLUBLE DRUGS WITH INCREASED STABILITY - The present invention provides stable pharmaceutical compositions of poorly water soluble pharmaceutical agents and stabilizing agents which function to increase stability of the compositions. The use of stabilizing agents provide extended stability of nanoparticle suspensions and other formulations of poorly water soluble pharmaceutical agents such as docetaxel under certain conditions, for example upon dilution for administration. | 2012-12-06 |
20120308613 | FORMULATIONS FOR USE IN INHALER DEVICES - A formulation for an inhaler device comprises carrier particles having a diameter of at least 50 μm and a mass median diameter of at least 175 μm; active particles; and additive material to which is able to promote release of the active particles from the carrier particles on actuation of the inhaler device. The formulation has excellent flowability even at relatively high fine particle contents. | 2012-12-06 |
20120308614 | COMPOSITION FOR THE CONTROLLED RELEASE OF BUPRENORPHINE - The present invention relates to a novel aqueous liquid pharmaceutical composition for the controlled release of buprenorphine or of an analogue of buprenorphine, comprising at least one prodrug with low aqueous solubility of said buprenorphine or analogue of buprenorphine, and at least one polymer having a linear backbone chosen from the polyglutamates, polyaspartates, poly(meth)acrylates and polysaccharides, to which one or more hydrophobic groups are grafted. | 2012-12-06 |
20120308615 | FORMULATION OF HEPATITIS B VIRUS ANTIGENS FOR CELLULAR STIMULATION FOLLOWED BY THERAPEUTIC IMMUNIZATION - The present invention is related with the field of the therapeutic immunization, specifically with the employment of a new formulation of antigens of the Hepatitis B Virus (HBV) for the cellular stimulation. The formulation is formed by the surface antigens (HBsAg) precipitated in suspension and the nucleocapsid (HBcAg) of the HBV. The formulation contains these antigens like suspended particles of sizes less than 500 nm and higher than 500 nm, in a mixture where the proportion among the particles of the mentioned sizes is among 50%-50% and 80%-20%, respectively. The selection of a range of sizes of particles allows that the levels of stimulation of several cellular types are maximized. Additionally, a cellular stimulation method is described with this formulation, and the later passive immunization of patients with chronic Hepatitis B, based on the maximum stimulation in vivo or in vitro using heterologous or autologous cells (dendritic cells, B cells and macrophages). The cells stimulated with this formulation are transferred to patients chronically infected with the HBV. | 2012-12-06 |
20120308616 | SUBMICRO EMULSION OF PACLITAXEL USING STEROID COMPLEX AS INTERMEDIATE CARRIER - A submicron emulsion of paclitaxel, the preparation method and the use thereof are disclosed. Said paclitaxel submicron emulsion comprises paclitaxel/steroid complex, oil for injection, water for injection, emulsifier, assistant emulsifier and isotonic agent, wherein the mole ratio of paclitaxel to steroid in the complex is 1:0.2˜4; preferably 1:0.25˜2. Said submicron emulsion is useful for the treatment for malignant tumor. The average particle diameter of the submicron emulsion is less than 400 nm and the pH Value is 3.5-6. | 2012-12-06 |
20120308617 | PHOSPHOLIPID-BASED INHALATION SYSTEM - The present invention includes a method for delivering medications deeper into the lungs and to the medications' pulmonary targets, which include bronchioles and alveoli. A first particularly preferred embodiment of the invention describes the use of two steps for delivery of a medication. In a first step, an aerosolized therapeutic composition or medication is administered into a patient's respiratory tract, wherein the patient may be any animal or human subject. Following the first step, an aerosolized surfactant is administered into the patient's respiratory tract that facilitates delivery of the aerosolized medication of the first step to the medication's pulmonary target. Another embodiment of the present invention contemplates an apparatus for the delivery of an aerosolized surfactant used that facilitates delivery of previously inhaled aerosolized medication. | 2012-12-06 |
20120308618 | IC31 NANOPARTICLES - The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL | 2012-12-06 |
20120308619 | COSMETIC ANTI-WRINKLE PATCH - A cosmetic patch is made of a thin adhesive-backed translucent polymer film tape releasably adhered to a release liner sheet, the polymer film tape being die-cut to provide at least one adhesive-backed removable section thereof sized shaped to fit a skin region of a wearer's face to inhibit creasing of the skin during sleep. | 2012-12-06 |
20120308620 | TOPICAL COSMETIC PREPARATION CONTAINING ELASTOGENESIS INDUCING SUBSTANCES ASSOCIATED WITH A SYSTEMIC ABSORPTION RETARDANT - A dermatological topical formulation such as a cream, ointment, or lotion containing an elastogenesis inducer and a systemic absorption retardant is described. Such a formulation achieves high local tissue concentration of the elastogenesis inducer in the vicinity of the application site, minimizes systemic absorption of the elastogenesis inducer, and maximizes a concentration of the elastogenesis inducer in dermis, resulting in formation or restoration of elastin fibers in adult skin. The formulation can further contain a skin penetration enhancer compound. | 2012-12-06 |
20120308621 | BASE FORMULATION FOR COSMETIC PRODUCTS - The present invention relates to a base formulation for cosmetic products, characterized in that it comprises, in percentage by weight of the formulation and according to the INCI nomenclature:
| 2012-12-06 |
20120308622 | Compositions of Apatite and Methods of Use - Compositions of apatite derivative crystals are disclosed herein. Also disclosed are methods of using these compositions to treat tooth sensitivity, to use as an anticaries treatment, to use as a restorative material, to use as a tooth surface whitener, and to combat or lessen the side effects of tooth whitening. | 2012-12-06 |
20120308623 | COMPOSITION COMPRISING NANOPARTICLES OF TI02 - The present invention is directed to a composition comprising nanoparticles of TiO | 2012-12-06 |
20120308624 | VISCOUS COMPOSITION - A viscous composition of the present invention comprises specific cellulose fibers (A), (A′) and (A″) which are selected according to uses of a cosmetic composition, a gel-like composition and a spray composition. By using the composition of the present invention, a cosmetic composition which is excellent in shape retention ability and dispersion stability and excellent in water tolerance to satisfy the properties and the performance which is necessary for cosmetics; a gel-like composition wherein gel-state can be kept without separation or water release; and wherein various functional additives which is necessary for the use is mixed without any problem can be obtained. | 2012-12-06 |
20120308625 | A METHOD FOR ALTERING THE FLAVOR OF A FOOD PRODUCT - A method for altering the flavor of a food product by impregnating a substance into a food product by exposing the food product to a pressure from 1000 to 6000 bar together with a solid compound containing the substance. The method further includes extracting the substance from the solid compound simultaneously with the step of impregnating. | 2012-12-06 |
20120308626 | COMPOSITION FOR CLEANING TEETH COMPRISING NATURAL GLASS AND RELATED METHODS - A composition for cleaning teeth may include natural glass, wherein the natural glass has a top particle size (d | 2012-12-06 |
20120308627 | LIQUID-FILLED PROTEIN-PHOSPHATIDIC ACID CAPSULE DISPERSIONS - The present invention generally relates to the field of membranes. In particular, the present invention relates to a composition comprising bodies surrounded by a membrane. The composition are for example edible compositions. One embodiment of the present invention relates to a composition containing an oily fraction, a hydrophilic fraction, and at least one body, wherein the body comprises a shell comprising several molecular layers of protein and at least one phosphatidic acid surfactant; and a content comprising an internal phase containing a hydrophilic component and/or a hydrophobic component. The composition may be used to protect a food product or to deliver specific properties to a product, for example. | 2012-12-06 |
20120308628 | COATED POWDER AND COSMETIC PREPARATION USING THE COATED POWDER - A coated powder is obtained by coating a powder to be treated, with a mixture, as a coating agent, which includes 60 wt % to 90 wt % of an extremely hardened plant fat and oil having a melting point of 50° C. or more and 10 wt % to 40 wt % of an ester oil agent derived from a plant fat and oil. The powder is coated with the coating agent preferably at a temperature higher than the melting point of the extremely hardened plant fat and oil by 10 to 20° C. The powder is coated with the coating agent in an amount of 1 wt % to 15 wt %, particularly preferably 3 wt % to 10 wt %. Further, cosmetic preparations can be obtained by using the coated powder as a part or an entire part of the cosmetic preparations. | 2012-12-06 |
20120308629 | INJECTABLE BULKING COMPOSITIONS - According to an aspect of the invention, injectable bulking compositions are provided which contain the following: (a) fibers that are configured to prevent migration to locations in the body remote from the injection site, for example, because they have a minimum length that is sufficiently large to prevent migration of the fibers and/or because they have surface features that stimulate host tissue response to lock the fibers in position and (b) a carrier in an amount effective to render the composition injectable. | 2012-12-06 |
20120308630 | TITANIUM DIOXIDE PHOTOCATALYTIC COMPOSITIONS AND USES THEREOF - Provided is a photocatalytic composition comprising zinc (Zn) doped titanium dioxide (TiO | 2012-12-06 |
20120308631 | AQUEOUS COATING COMPOSITIONS - A pesticidal coating composition is provided which comprises an aqueous dispersion of at least one film-forming binder and at least one microencapsulated pesticide; wherein a coating prepared from such composition is substantially water-impermeable upon curing. The present invention further provides methods of coating substrates with the pesticidal coating composition, as well as substrates coated with the composition. The pesticidal coating compositions of the invention can be applied to substrates by professionals or non-professionals by spraying, painting, rolling, or brushing, before, during, or after construction. | 2012-12-06 |
20120308632 | USE OF BACTERIAL POLYSACCHARIDES FOR BIOFILM INHIBITION - A method comprises preventing or inhibiting bacterial adhesion and/or bacterial biofilm development by treating a substrate with a composition of a soluble group II capsular polysaccharide obtained from a bacterial strain. | 2012-12-06 |
20120308633 | NANOSTRUCTURED MATERIAL FORMULATED WITH BONE CEMENT FOR EFFECTIVE ANTIBIOTIC DELIVERY - This invention uses mesoporous silica nanoparticles and other nanostructured materials to formulate polyacrylate-based bone cement for achieving an enhanced and controlled elution of active ingredients such as antibiotics. This invention overcomes the limitation of low antibiotic release from commercial polyacrylate-based bone cements using for example, PMMA. In certain aspects, the formulation enables a sustained release of antibiotics from the bone cement over a period of 80 days and achieves 70% of total drug release, whereas the commercial antibiotic bone cement (e.g., SmartSet GHV) only releases about 5% of the antibiotics on the first day and subsequently an almost negligible amount. In addition, the mechanical properties of our formulated bone cements are well retained. The inventive bone cement exhibits good antibacterial properties and has very low cytotoxicity to mouse fibroblast cells. | 2012-12-06 |
20120308634 | GUM DELIVERY SYSTEM - A new chewing gum comprising a gum member, with a central core or cavity, and a core element located within the central core or cavity. The chewing gum also comprises a dietary supplement, which may be incorporated in the central core, the cavity, or both. The core element can be of a range of consistencies, from fluid to gel-like. Optionally, the gum member may comprise crystals. Additionally, the crystals may comprise a dietary supplement. The chewing gum may be encapsulated with a coating. Multiple dietary supplements, of different or of the same varieties, may be incorporated into the chewing gum. | 2012-12-06 |
20120308635 | MELT EXTRUDED THIN STRIPS CONTAINING COATED PHARMACEUTICAL - A composition suitable for hot melt extrusion to form thin strips containing active pharmaceutical ingredients is provided. The composition has 10 to 75% by weight of polyethylene oxide having a molecular weight of from 70,000 to 230,000 Daltons; 5 to 35% of a sugar alcohol having a melting point in excess of 75° C.; 5 to 20% by weight of polyethylene glycol having a molecular weight of from 100 to 4,000 Daltons; and 10 to 75% by weight of coated active pharmaceutical ingredient (API). | 2012-12-06 |
20120308636 | Multi-Layer Antimicrobial Wound Dressing - A multi-layer antimicrobial wound dressing includes a wound-contacting layer and an antimicrobial layer. The wound contacting layer includes a biocompatible fibrous matrix that is made of an anionic polymer, and the antimicrobial layer is made of a cationic polymer that is connected to the wound-contacting layer via anionic-cationic interaction between the anionic polymer of the fibrous matrix and the cationic polymer of the antimicrobial layer. | 2012-12-06 |
20120308637 | COMPOSITIONS COMPRISING EXTRACTS OF BOSWELLIA, TEA TREE, ALOE AND LAVENDER OIL AND METHODS OF TREATING WOUNDS, BURNS AND SKIN INJURIES THEREWITH - Compositions for the treatment of sores, wounds, burns and other traumatized dermal tissues and skin injuries comprising | 2012-12-06 |
20120308638 | ANTIMICROBIAL PEPTIDES - The present invention provides novel therapeutic antimicrobial peptides that are bactericides and have an inhibitory effect on biofilms produced by biofilm-forming bacteria and especially biofilm-forming staphyloccocal bacteria. The invention includes the nucleic acids encoding the polypeptides, methods of treating bacterial infections, medical devices or implants or prosthetics impregnated with, covered or coated in the polypeptides, and means of delivery of the peptide to the oral cavity. | 2012-12-06 |
20120308639 | Mesocellular Oxide Foams as Hemostatic Compositions and Methods of Use - The present invention relates to hemostatic compositions comprising a mesocellular oxide foam and, optionally, a biologically active agent such as a procoagulant, as well as devices and methods of use to promote blood clotting. | 2012-12-06 |
20120308640 | AMPHIPHILIC JANUS-DENDRIMERS - The invention concerns compounds of the formula: X—(Y) | 2012-12-06 |
20120308641 | Compositions and Methods for Enhancing Coagulation Factor VIII Function - Factor VIII variants and methods of use thereof are disclosed. | 2012-12-06 |
20120308642 | INHIBITING HEPATITIS C VIRAL REPLICATION WITH SIRNA COMBINATIONS - Compositions are disclosed of combinations of small interfering RNAs (siRNA) that can inhibit the replication of hepatitis C virus (HCV) in liver cells, along with methods of co-administering the siRNAs to subjects. Further, methods are disclosed for improving the delivery of nucleic acids to the liver. | 2012-12-06 |
20120308643 | LIPOSOMAL MITIGATION OF DRUG-INDUCED LONG QT SYNDROME AND POTASSIUM DELAYED-RECTIFIER CURRENT - Compositions and methods for the treatment of drug-induced long QT syndrome and other cardiac channelopathies are disclosed herein. The compositions and methods of the present invention comprise binding one or more QT prolonging drugs with a liposome prior to parenteral (intravenous or subcutaneous) administration, or administration of an empty liposome prior to or concomitantly with therapeutic agents known to have a high risk of QT prolongation, or immediately following an envenomation. The results presented show an abrogation of the adverse effects of QT prolonging drugs in a dose-dependent manner by the compositions of the present invention. | 2012-12-06 |
20120308644 | Compositions for mucosal delivery of agents - Compositions and methods for mucosal delivery of agents are provided. The compositions are intended for administration to mucosal surface, such as oral, gastrointestinal and nasal mucosa. The compositions provided contain one or more mucoadhesive proteins and an agent to be delivered. Methods for delivery of agents using the compositions provided herein are also provided. | 2012-12-06 |
20120308645 | COMPOSITIONS AND METHODS FOR SIRNA INHIBITION OF HIF-1 ALPHA - RNA interference using small interfering RNAs which target HIF-1 alpha mRNA inhibit expression of the HIF-1 alpha gene. As HIF-1 alpha is a transcriptional regulator of VEGF, expression of VEGF is also inhibited. Control of VEGF production through siRNA-mediated down-regulation of HIF-1 alpha can be used to inhibit angiogenesis, in particularly in diseases such as diabetic retinopathy, age related macular degeneration and many types of cancer. | 2012-12-06 |
20120308646 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES - Aminoside tetracyclic anthraquinones represented by formula (I) and (II). Peptides are introduced to connect tetracyclic anthraquinones and fatty acid to enable selective absorption and release of the anticancer agents. In addition, aminosaccharide and tetracyclic moieties are introduced into the branched chain to improve water-solubility. The compounds of formula (I) and (II) are pharmaceutically active components useful for treating diseases that are cured by aminoside tetracyclic anthraquinones, including cancer. | 2012-12-06 |
20120308647 | USE OF MIR-30E TO TREAT VASCULAR LESIONS - MicroRNA molecules are directed to the treatment of diseases associated with plaque formation, cardiovascular diseases, inflammation, stroke, and disorders associated with aging. | 2012-12-06 |
20120308648 | METHODS OF TREATING HOT FLASHES WITH FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION - The present invention relates generally to methods for treating hot flashes by administering formulations for transdermal or transmucosal administration of estrogen. The formulations of the invention are effective at treating hot flashes at surprisingly low daily doses, preferably the lowest effective dose of estrogen to treat hot flashes, e.g., about 0.45 to about 0.6 mg of estrogen per day. The amount of estrogen which is administered produces an estimated nominal daily estrogen dose in a subject undergoing treatment of from about 10 to about 15 micrograms, and a serum estradiol level of between about 25 pg/ml to about 50 pg/ml. The preferred formulations are substantially free of malodorous, and irritation causing long-chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. | 2012-12-06 |
20120308649 | Bacterial cellulose composite with capsules embedded therein and preparation thereof - A composite of bacterial cellulose and capsules embedded therein is prepared, for example calcium alginate capsules encapsulating functional components being discretely embedded in a matrix of | 2012-12-06 |
20120308650 | MODIFIED ALGINATES FOR CELL ENCAPSULATION AND CELL THERAPY - Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers. | 2012-12-06 |
20120308651 | SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF - Salts of benzimidazolyl pyridyl ethers are provided, particularly salts of {1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy]-1H-benzoimidazol-2-yl}-(4-trifluoromethyl-phenyl)amine. Compositions and formulations including such salts and surfactants as well as methods of preparing such compositions and formulations are provided. | 2012-12-06 |
20120308652 | ORAL FORM OF ADMINISTRATION COMPRISING ENTECAVIR - The invention relates to pharmaceutical formulations, preferably in the form of an oral dosage form, for the treatment of chronic hepatitis-B virus infections, containing micronised Entecavir, and processes for preparing it. The invention further relates to intermediates containing micronised entecavir, in which the D50 value for the particle size distribution is less than 50 μm, and processes for preparing them. | 2012-12-06 |
20120308653 | WORMWOOD PILL CONTAINING 95% OF WORMWOOD ETHYL ALCOHOL EXTRACT THAT HAS INACTIVATION EFFICACY OF THE H1N1 VIRUS AND THE H9N2 AVIAN INFLUENZA VIRUS - A mugwort pill containing a 95% ethanol extract of wormwood having an inactivation power with respect to a novel swine-origin influenza virus and an avian influenza virus is disclosed. In more details, the conventional mugwort pill is prepared by a hot water extraction method and has 0.8% of crude fat component; however the ethanol extract mugwort crude fat of the present invention is 11.6%, in particular the crude fat component is 14.5 times higher, and the novel swine-origin influenza virus (H1N1) can be inactivated 99.99%, and it has a good disinfection effect to an avian influenza virus (H9N2). When a mugwort pill containing a 95% ethanol extract of wormwood having an inactivation power with respect to a novel swine-origin influenza virus and an avian influenza virus is administrated to people or fowls, the people or fowls can have immunity with respect to a novel swine-origin influenza virus and an avian influenza virus. | 2012-12-06 |
20120308654 | ABUSE-PROOFED DOSAGE FORM - A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid. | 2012-12-06 |
20120308655 | Delivery Carrier - The present invention relates to a novel liquid delivery carrier comprising a specific grade of glyceryl caprylate and PEG-40 hydrogenated castor oil in particular amounts. This carrier can be loaded with slightly or poorly water soluble substances and filled into hard gelatin capsule shells for final administration to a subject. Also disclosed are filling compositions comprising such delivery carrier and hard gelatin capsules filled with the carrier and the composition of the invention. The delivery carrier of the invention proved to be compatible with both the hard gelatin capsule shells and the substances loaded into it. | 2012-12-06 |
20120308656 | SUGAR-COATED PREPARATION AND PRODUCTION METHOD FOR THE SAME - A method is provided for producing a sugar-coated preparation including a solid composition containing a pharmacologically active ingredient and a sugar coating layer. The method comprises a step of forming the sugar coating layer with a sugar coating composition containing one or more sugar-alcohols selected from the group consisting of mannitol and erythritol and a polyvinyl alcohol-based resin. The sugar-coated preparation includes a solid composition containing a pharmacologically active ingredient and a sugar coating layer, wherein the sugar coating layer is made of a sugar coating composition containing one or more sugar-alcohols selected from the group consisting of mannitol and erythritol and a polyvinyl alcohol-based resin. | 2012-12-06 |